Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13140240 | 0.84 | L3MBTL1 (0.60) | LTA4HL3MBTL1ALDH1A1HDAC3HDAC4 | |
| SCHEMBL204739 | 0.84 | L3MBTL1 (0.56) | LTA4HL3MBTL1ALDH1A1HDAC3HDAC4 | |
| SCHEMBL201719 | 0.84 | L3MBTL1 (0.60) | LTA4HL3MBTL1ALDH1A1HDAC3HDAC4 | |
| SCHEMBL15229059 | 0.84 | LTA4H (0.42) | LTA4HL3MBTL1ALDH1A1HDAC3HDAC4 | |
| SCHEMBL4522401 | 0.84 | L3MBTL1 (0.56) | LTA4HL3MBTL1ALDH1A1HDAC3HDAC4 | |
| SCHEMBL16217975 | 0.82 | MEN1 (0.52) | LTA4HALDH1A1LOXL2MEN1KMT2A | |
| SCHEMBL14672195 | 0.81 | ALDH1A1 (0.62) | L3MBTL1ALDH1A1LOXL2MEN1KMT2A | |
| SCHEMBL4190251 | 0.81 | HDAC1 (0.60) | LTA4HL3MBTL1ALDH1A1HDAC3HDAC4 | |
| SCHEMBL16217974 | 0.80 | HDAC3 (0.56) | LTA4HL3MBTL1ALDH1A1HDAC3HDAC4 | |
| SCHEMBL2225749 | 0.80 | L3MBTL1 (0.53) | LTA4HL3MBTL1ALDH1A1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562043-B2 | Heterocyclic amide derivative and pharmaceutical product containing same | EA PHARMA CO., LTD. (JP) | 2017-02-07 | — | — | US | disclosed |
| US-9562043-B2 | Heterocyclic amide derivative and pharmaceutical product containing same | EA PHARMA CO., LTD. (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20140329796-A1 | HETEROCYCLIC AMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | AJINOMOTO CO., INC. (JP) | 2014-11-06 | — | — | US | disclosed |
| US-20140329796-A1 | HETEROCYCLIC AMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | AJINOMOTO CO., INC. (JP) | 2014-11-06 | — | — | US | disclosed |
| WO-2007089557-A2 | POLYCYCLIC 1, 2, 3, 4 -TETRAHYDRO- ISOQUINOLINE DERIVATIVES AND COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS | IRM LLC (BM) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329796-A1 | HETEROCYCLIC AMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | TRPA1, TRPV1, TRPV2 | LTA4H 327/4885L3MBTL1 4745/4885ALDH1A1 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.